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Introduction
Resistance against chemotherapeutic agents is still a major 
obstacle for effective cancer therapy (Krishna and Mayer 
2000), and the search for alternative therapeutic strategies and 
cancer-specific targets to efficiently treat cancer is stronger 
than ever (Volm and Efferth 2015). TRAIL, the tumor necro-
sis factor-related apoptosis-inducing ligand, is a promis-
ing candidate for cancer treatment and its soluble form is 
already in clinical trials, with limited success (Cheah et al. 
2015). TRAIL is expressed on the surface of immune cells 
and binds to five different receptors. Two of them, TRAIL-
R1 and TRAIL-R2, induce caspase activation and apoptotic 
cell death after ligand binding. TRAIL-R3 and TRAIL-R4 
are decoy receptors, also expressed on the cell surface but 
lacking functional intracellular death domains (LeBlanc and 
Ashkenazi 2003). TRAIL-R5, also known as osteoprotegerin, 
is a soluble receptor and does not induce apoptosis (Emery 
et al. 1998). Compared to other death receptors, e.g., TNF 
or CD95, TRAIL is well tolerated, has low side effects and 
shows potent anti-tumor effect (Ashkenazi et al. 1999).
However, there are several generic problems using sol-
uble TRAIL in therapy. Soluble TRAIL has a low in vivo 
half-life and less activation of TRAIL-R2, one of the two 
death receptors (Kelley et al. 2001; Muhlenbeck 2000). 
Therefore, relative high doses of active TRAIL are required 
and the selectivity for tumor cells may be lost. Addition-
ally, TRAIL-R2 activity has been reported to increase inva-
siveness and metastatic potential of tumors (von Karstedt 
et al. 2015), making necessary a careful assessment of the 
therapeutic use of TRAIL.
Abstract Resisting cell death is one of the hallmarks of 
cancer, and represents a common problem resulting in inef-
fective cancer therapy. To overcome resistance to apopto-
sis, we designed an antibody-based therapy strategy using 
Kv10.1 as a target. Kv10.1 is a voltage-gated potassium 
channel, which has been identified as a tumor marker sev-
eral years ago. The agent consists of a Kv10.1-specific sin-
gle-chain antibody fused to the soluble tumor necrosis fac-
tor-related apoptosis-inducing ligand (scFv62-TRAIL). We 
combined scFv62-TRAIL with different chemotherapeutic 
drugs, all of which failed to induce apoptosis when used 
alone. In the combination, we could overcome the resist-
ance and selectively induce apoptosis. Among the drugs, 
doxorubicin showed the most promising effect. Addition-
ally, we observed improved efficacy by pre-treating the 
cells with doxorubicin before scFv62-TRAIL application. 
Expression analysis of the TRAIL death receptors suggests 
a doxorubicin-induced increase in the abundance of recep-
tors as the mechanism for sensitization. Furthermore, we 
confirmed the anti-tumor effect and efficacy of our combi-
nation strategy in vivo in SCID mice bearing subcutaneous 
tumors. In conclusion, we propose a novel strategy to over-
come resistance to chemotherapy in cancer cells. Doxoru-
bicin and scFv62-TRAIL reciprocally sensitize the cells to 
each other, specifically in Kv10.1-positive tumor cells.
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We have previously reported the generation and initial 
characterization of a single-chain antibody-TRAIL fusion. 
The antibody targets residues 402–410 in the extracellular 
funnel of the pore of Kv10.1 (Gomez-Varela et al. 2007), a 
voltage-gated potassium channel that is very abundant in neu-
rones, but also expressed by many non-neural tissues over a 
time window in G2/M phases of the cell cycle (Urrego et al. 
2016). More than 70 % of tumor tissues and tumor cells from 
different origin express robustly the channel (Ding et al. 
2007; Farias et al. 2004; Hemmerlein et al. 2006; Mello de 
Queiroz et al. 2006; Rodriguez-Rasgado et al. 2012). Down-
regulation using siRNA or blocking of the channel lead to 
growth inhibition of cancer cells in vitro and in vivo (Garcia-
Ferreiro et al. 2004; Gomez-Varela et al. 2007; Weber et al. 
2006); siRNA knockdown of Kv10.1 shows synergistic 
effects with TRAIL overexpression in osteosarcoma models 
(Wu et al. 2013). There is also evidence that anti-depressants 
able to block Kv10.1 improve survival in brain metastases 
moderately expressing Kv10.1 in human patients (Martinez 
et al. 2015). Therefore, cancer cells seem to take an advantage 
of expressing Kv10.1 and this cancer-restricted expression of 
the channel and the accessibility from the external environ-
ment turn the channel into a promising therapeutic target.
The cancer-selectivity and the potent apoptosis-inducing 
effect have been shown already in our previous study with 
prostate cancer cells (Hartung et al. 2011) in vitro. Here we 
extend and deepen our understanding on the mechanisms 
of sensitization, and provide the first evidence of efficacy 
in vivo using a xenograft tumor mouse model.
Materials and methods
Unless otherwise indicated, reagents were obtained from 
Sigma-Aldrich (Munich, Germany).
Cell culture
MDA-MB435S (ATCC HT29) was purchased from ATCC, 
and CHO-K1 (ACC-110) from DSMZ. MDA-MB435S 
cells were cultured in RPMI 1640 with 10 % FCS and 
CHO-K1 cells in Ham’s F-12 medium with 10 % FCS, or in 
protein-free expression medium Panserin C6000 at 37 °C in 
humidified 5 % CO2 atmosphere. Transfection of scFv62-
TRAIL in CHO-K1 cells was done with Lipofectamine 
2000 (Thermo Fisher Scientific) as recommended by the 
manufacturer. siRNA against Kv10.1 (Weber et al. 2006), 
TRAIL-R1 and/or TRAIL-R2 (both from Santa Cruz) 
was transfected using Lipofectamine RNAi Max (Thermo 
Fisher Scientific). The cells were treated with scFv62-
TRAIL and Cycloheximide (CHX) 24 h after siRNA trans-
fection and 20 h later apoptosis induction was analyzed.
Production of scFv62‑TRAIL
Supernatant from transfected CHO-K1 cell culture contain-
ing the scFv62-TRAIL was concentrated with Centricon 
YM-100 (Millipore), and sterile filtered. Purification was 
performed using affinity chromatography in a BioCAD 
Vision Workstation (Persective/Applied Biosystems). The 
affinity column was prepared using Self Pack POROS 20 
EP coupled to the fusion protein used to generate the anti-
body (h1x) (Hemmerlein et al. 2006) Cell medium con-
taining the scFv62-TRAIL construct was loaded on the 
column, washed with PBS pH 7.5 and eluted by acidic pH 
(100 mM Glycine/150 mM NaCl pH 2.4). The elution peak 
was collected in an automated fraction collector and neu-
tralized with 1 M Tris–HCl pH 8.0.
Active scFv62-TRAIL concentration was determined 
based on the amount of TRAIL detected using a commer-
cial ELISA (R&D Systems) according to the manufacturer 
protocol.
Flow cytometry
Analysis of the apoptosis-inducing potential of scFv62-
TRAIL was performed using Annexin V assays in a flow 
cytometer (BD FACS Aria). The cells were seeded at 
1 × 105 per well in 12-well plates and treated with various 
concentrations of scFv62-TRAIL in combination with 5 µg/
ml (17.77 µM) CHX for the indicated times. Apoptotic cells 
were determined using the Annexin V-FITC/PI staining kit 
(Imgenex, San Diego, CA, USA) or Annexin-Alexa647 
(Molecular Probes, Thermo Fisher Scientific) according to 
the manufacturer’s recommendations. Annexin V-positive 
cells were defined as apoptotic cells including early and 
late apoptotic cells.
Surface plasmon resonance (SPR)
scFv62-TRAIL purified as above was dialyzed against 
HBS buffer, and protein concentration was determined 
using BCA protein assay (Thermo Fisher Scientific). The 
ligand used was h1x, coupled to a CM5 chip (GE Health-
care, Uppsala, Sweden) according to the instructions from 
the manufacturer at pH 4.5. Association and dissociation 
constants were determined in a BIAcore 2000 device. The 
concentration mentioned was calculated as total protein 
concentration assuming purity and the predicted molecular 
mass of 153 kDa. The fusion protein was diluted in buffer 
HBS-EP to concentrations ranging from 3.8 to 30.8 nM and 
injected on the flow cell. The BIAevaluation software was 
used for analysis and data were fitted to a 1:1 Langmuir 
model for determination of affinity, association, and disso-
ciation constants.
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Quantitative real‑time PCR
Total RNA was obtained from cells using the RNAeasy 
mini kit (Qiagen, Hilden, Germany) and first strand cDNA 
was produced using SuperScript (Thermo Fisher Scientific). 
Real-time PCR was performed with 100 ng cDNA using the 
TaqMan system in Light Cycler 480 (Roche Diagnostics). 
The housekeeping genes human transferrin receptor and 
human actin were used as a control of RNA integrity and 
for quantification. Specific mRNA content was determined 
using the Light Cycler 480 software. For all genes the UPL 
probe system from Roche Diagnostics was used.
In vivo study
Animal studies were performed according to the German 
law and with the approval by the local animal ethics com-
mittee. We used 8-week-old female CB17/Icr-Prkdcscid/
IcrCr mice (Charles River), housed in individually venti-
lated cages (two mice per cage), with free access to food 
(autoclaved pellets) and water. At the start of the experi-
ment, mice were injected subcutaneously (s.c.) in the right 
side flank with 5 × 106 MDA-MB435S cells in 200 µl PBS. 
The area of injection had been previously shaved and was 
maintained without hair to minimize measurement errors. 
Starting at 3 weeks, tumor size was controlled weekly by 
measuring the major axis (length) and a perpendicular diam-
eter (width), using a caliper always by the same operator. 
Tumor volume was calculated with the following formula: 
tumor volume = length × width2 × 0.52. The animals were 
randomized after the first measurement point in four groups: 
(A) control, (B) doxorubicin (freshly prepared in PBS), (C) 
scFv62-TRAIL, and (D) doxorubicin in combination with 
scFv62-TRAIL. One treatment cycle lasted 4 days. On day 
1, group A and C received 200 µl PBS and group B and C 
200 µl doxorubicin in PBS (0.9 mg/kg). On the following 
2 days, mice received scFv62-TRAIL (0.15 mg/kg) (group 
C and D) or PBS (group A and B). On day 4, mice were 
not treated. After three cycles, the dose of scFv62-TRAIL 
was reduced: On day 1, group A and C received 200 µl PBS 
and group B and C 200 µl PBS and doxorubicin (0.9 mg/
kg). The following days, mice received scFv62-TRAIL 
(0.15 mg/kg) (group C and D) or PBS (group A and B). 
On days 3 and 4, mice were not treated. Tumor growth and 
body weight were measured once per week. Six weeks after 
tumor implantation, the animals were killed and the tumors 
were dissected and weighted.
Statistical analysis
Data were analyzed using GraphPad Prism and are repre-
sented as mean ± SEM. At least two independent experi-
ments were performed for each analysis. Statistical 
significance was evaluated by Student’s t test and two-way 
ANOVA.
Results
Combination of chemotherapeutic agents 
and scFv62‑TRAIL can overcome resistance and induce 
apoptosis in MDA‑MB435S cells
The construction and production of the Kv10.1-specific 
single-chain antibody fused to the soluble TRAIL (scFv62-
TRAIL) has been described before. The scFv62-TRAIL 
was expressed in CHO-K1, concentrated and concentra-
tion was determined using a commercial TRAIL ELISA 
and is therefore reported as equivalent TRAIL concentra-
tion in the preparation. The expression yield was ~5 µg/
ml. The selectivity for Kv10.1 expressing cancer cells and 
the potent apoptosis induction of our fusion construct was 
already demonstrated with prostate cancer cells.
The highly metastatic and Kv10.1-positive cancer cell 
line MDA-MB435S is described to be resistant against many 
chemotherapeutic agents and also to TRAIL-induced apop-
tosis (Grosse-Wilde and Kemp 2008; Ortiz-Ferrón et al. 
2008). We treated the MDA-MB435S cells with six conven-
tionally used chemotherapeutic drugs in combination with 
scFv62-TRAIL (Fig. 1a). Treatment with scFv62-TRAIL 
alone did not induce a detectable increase of apoptotic cells. 
Only paclitaxel and doxorubicin induced significant levels of 
apoptotic cells when applied alone. The scFv62-TRAIL in 
combinational treatment increased significantly the amount 
of apoptotic cells for all tested agents. The most intense 
effect was observed with cycloheximide (CHX), roscovitine, 
and doxorubicin. Paclitaxel alone showed apoptosis induc-
tion of around 18 % and in combination with scFv62-TRAIL 
an apoptotic rate of 35 %. Also, CHX in combination with 
scFv62-TRAIL induced apoptosis in 40 % of the cells. 
scFv62-TRAIL in combination with cisplatin and etoposide 
induced a weak but statistically significant effect.
The sensitizing effect of scFv62-TRAIL to etoposide, 
doxorubicin, and roscovitine was dose-dependent. We 
treated the cells with different concentrations of the drugs 
alone or in combination (Fig. 1b–e). The scFv62-TRAIL 
increased the efficacy of all three drugs in all concentra-
tions used in an almost linear fashion. The sensitization lost 
linearity only for the highest concentration of doxorubicin; 
the very high value of 80 % apoptotic cells could have satu-
rated the detection capability of Annexin V.
scFv62‑TRAIL retains its affinity for the antigen
The single-chain antibody was cloned starting from a 
mouse hybridoma mAb62 (Hemmerlein et al. 2006) and 
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fused to soluble TRAIL. To confirm that the antibody part 
still recognizes the antigen, we performed surface plas-
mon resonance (SPR) experiments (Fig. 2a). The fusion 
protein used as an antigen served as a ligand bound to the 
chip, and the scFv62-TRAIL construct was the analyte. 
The sensorgrams obtained with different concentrations of 
the analyte (3.8–30.8 nM) indicate an affinity of 0.67 nM. 
We are not in a situation to directly compare this value 
with the intact antibody or the single chain alone because 
the stoichiometry of the TRAIL fusion construct (trimer) is 
Fig. 1  TRAIL-induced apoptosis in the presence of chemothera-
peutic agents in MDA-MB435S cells. a MDA-MB435S cells were 
treated with the indicated chemotherapeutics (10 μM etoposide, 
10 μM cisplatin, 20 μM roscovitine, 10 μM paclitaxel, 1 μM dox-
orubicin, 0.5 μg/ml CHX) in combination with scFv62-TRAIL 
(0.1 μg/ml) for 18 h. Apoptosis was determined by Annexin V stain-
ing and flow cytometry. Asterisks indicate statistical significance 
(**p < 0.01; ****p < 0.0001; two-way ANOVA). MDA-MB435S 
cells were treated with scFv62-TRAIL (0.1 μg/ml) with different 
concentrations of etoposide (b), doxorubicin (c), and roscovitine (d) 
and analyzed with Annexin V staining and flow cytometry. e Data 
from b–d are represented as percent apoptosis in the presence of 
scFv62-TRAIL versus apoptosis induction in the absence of the con-
struct. The synergistic effect was comparable for all drugs and line-
arly correlated to the concentration of the drug
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different from that of the antibody (dimer). However, we 
can nevertheless conclude that the scFv retains a reasonable 
affinity after fusion with TRAIL.
Induction of apoptosis by scFv62‑TRAIL requires 
both active TRAIL and a binding antibody moiety
To test if both active parts of the construct are required for 
its action, scFv62-TRAIL was pre-incubated with a neu-
tralizing anti-TRAIL antibody (at a 10:1 ratio for 1 h) or 
with a fusion protein containing the epitope for scFv62 
(h1x; 50:1 for 1 h), in order to block TRAIL—or the anti-
body binding site (Fig. 2b). MDA MB435S cells were sub-
sequently treated with the preincubated construct in the 
presence of 5 µg/ml CHX for 18 h (Fig. 2b). Both the anti-
TRAIL antibody and the antigen blocked the effect of the 
construct and resulted in significant reduction of apoptosis 
induction; blocking of TRAIL showed a stronger reduc-
tion of the efficacy. Therefore, we conclude that both moi-
eties in scFv62-TRAIL are required to efficiently induce 
apoptosis.
scFv62‑TRAIL acts though both TRAIL‑R1 
and TRAIL‑R2
There are two TRAIL receptors that mediate the apoptosis 
signal. Different studies demonstrated that TRAIL induces 
apoptosis predominantly via TRAIL-R1 in some cancer cell 
lines and via TRAIL-R2 in others. By real-time RT-PCR on 
mRNA obtained from MDA-MB435S cells, we found that 
both apoptosis inducing receptors (Kim et al. 2000) were 
expressed at significant levels, TRAIL-R2 being slightly 
more abundant than TRAIL-R1 (Fig. 3a). The levels of 
mRNA were normalized using both human transferrin 
receptor and human actin as invariably expressed genes. 
The decoy receptor TRAIL-R3 was scarce, and TRAIL-R4 
was not detected.
To test which receptors are required for the action of 
scFv62-TRAIL, we knocked down the TRAIL apopto-
sis receptors with specific siRNAs before treatment with 
scFv62-TRAIL in combination with CHX (Fig. 3b). The 
presence of TRAIL-R1 or R2 was enough to maintain 
the efficacy of the construct. Only downregulation of 
both receptors together completely blocked the TRAIL-
mediated apoptosis induction. Therefore, scFv62-TRAIL 
can induce apoptosis through either of the two death 
receptors.
Pre‑sensitizing effect of the chemotherapeutic agents
Sensitizing with chemotherapeutic agents is a commonly 
used strategy to make cancer cells susceptible to TRAIL-
induced apoptosis. The exact mechanism responsible for 
the sensitizing effect is not clear for every agent; there are 
many different steps in the apoptosis machinery that can 
be altered to become resistant against TRAIL. Since there 
was no or only poor expression of the decoy receptors, we 
focused on the expression rate of the apoptotic receptors 
(Fig. 4). We treated the MDA-MB435S cells with etopo-
side, doxorubicin, and roscovitine for 24 and 48 h and 
analyzed the mRNA abundance of TRAIL receptors and 
Kv10.1 by real-time PCR (Fig. 4). The amount of TRAIL-
R1 and TRAIL-R2 was dramatically increased already after 
24-h etoposide and doxorubicin treatment (Fig. 4a, b). Sur-
prisingly, roscovitine induced a downregulation of TRAIL-
R1 and TRAIL-R2 after 24 h and upregulation after 48 h 
Fig. 2  Analysis of scFv62-TRAIL induced apoptosis. a Associa-
tion and dissociation constants between the immunogen (h1x) and 
the scFv62-TRAIL construct were determined by SPR. Sensograms 
were recorded for binding of the indicated concentrations of scFv62-
TRAIL (analyte) to immobilized h1x (ligand). b Apoptosis induc-
tion by scFv62-TRAIL requires both the antibody part and active 
TRAIL. MDA-MB435S cells were treated with scFv62-TRAIL that 
had been pre-incubated with excess antigen (1:50) or with neutral-
izing anti-TRAIL antibody (1:10) for 1 h. Apoptosis induction was 
analyzed with Annexin V staining and flow cytometry 18 h after the 
addition 0.1 µg/ml scFv62-TRAIL and 0.5 μg/ml CHX. Student’s t 
test, **p < 0.01, ***p < 0.001
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treatment. TRAIL-R3 and TRAIL-R4 were virtually absent 
before and after treatment (Fig. 4c; note the different scale 
compared to a and b). Only etoposide induced a significant 
increase in Kv10.1 expression—up to 4 times—after treat-
ment for 24 and 48 h (Fig. 4d). This could reflect the arrest 
in G2 typical of topoisomerase inhibitors (Clifford et al. 
2003; Kolb et al. 2012; Wu et al. 2010), because Kv10.1 
expression is maximal at this phase of the cell cycle 
(Urrego et al. 2016).
To explore the impact the changes in the expression 
of the apoptosis receptors and Kv10.1 on the efficacy of 
scFv62TRAIL, we pre-treated the MDA-MB435S cells 
with different concentrations of doxorubicin for 24 h and 
subsequently added scFv62-TRAIL for 18 h (Fig. 5a). 
Compared to the combinational treatment, we observed 
an increase of up to 25 % more apoptotic cells with the 
doxorubicin pre-treatment, which we attribute to the higher 
abundance of receptors.
Since we observed the highest apoptosis rate with doxo-
rubicin, this agent was used for all following in vitro and 
in vivo experiments in combination with scFv62-TRAIL. 
To investigate the sensitizing effect of doxorubicin, we 
performed a pulse-treatment experiment. MDA-MB345S 
cells were treated with 0.5 μM doxorubicin for 24 h and 
afterwards with scFv62-TRAIL for different time spans in 
the presence or absence of doxorubicin (Fig. 5b). 1-h expo-
sure to scFv62-TRAIL was already sufficient to induce the 
maximal apoptotic effect on MDA-MB435S cells, indepen-
dently of the presence of doxorubicin. However, continued 
presence of doxorubicin increased the apoptosis induction 
at all times tested.
Doxorubicin in combination with scFv62‑TRAIL 
reduced tumor growth in vivo
Based on the in vitro data, we performed an in vivo study 
with SCID mice carrying MDA-MB435S tumors. 5 × 106 
MDA-MB435S cells were injected s.c. into the flank of 
8-week-old female CB17/Icr-Prkdcscid/IcrCr mice. When 
the tumors reached a measurable size (~150 mm3), the 
animals were randomized into four groups (12 animals 
per group) with similar means and standard deviation, and 
the treatment was started using intraperitoneal injections 
of doxorubicin (0.9 mg/kg) on day 1, and scFv62-TRAIL 
(0.15 mg/kg) on days 2 and 3. This loading cycle was 
repeated three times, allowing 1 day between cycles. Sub-
sequently, doxorubicin and scFv62-TRAIL were adminis-
tered on days 1 and 2, respectively, and days 3 and 4 the 
mice were not treated (Fig. 6a). In the corresponding con-
trol groups, the omitted agent was substituted by an equal 
volume of the vehicle (PBS). After six treatment cycles, 
a strong decrease of tumor growth was detected in mice 
treated with a combination of doxorubicin and scFv62-
TRAIL (Fig. 6b). Ex vivo analysis of the tumor weight 
confirmed a significant reduction of the tumors in the mice 
that received the combinational treatment compared to the 
other groups (Fig. 6c).
Discussion
A growing body of evidence demonstrates the involvement 
of ion channels in the hallmarks of cancer (Hanahan and 
Fig. 3  a Expression of TRAIL receptors mRNA in MDA-MB435S. 
Quantitative real-time PCR on cDNA from the cell line revealed 
abundant message for TRAIL-R1 and TRAIL-R2, the latter being 
more abundant. b Both TRAIL-R1 and TRAIL-R2 can mediate the 
effect to scFv62-TRAIL. MDA-MB435S cells were treated with 
siRNA against, TRAIL-R1, TRAIL-R2, or both apoptotic receptors 
in combination (30 nM); 24 h later cells were treated with scFv62-
TRAIL (0.1 μg/ml) in combination with 0.5 μg/ml CHX for 18 h. 
Apoptosis induction was measured with Annexin V staining and flow 
cytometry. Only when both receptors were knocked one there was a 
significant reduction in apoptosis induction
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Weinberg 2011; Prevarskaya et al. 2010). Among ion chan-
nels, the voltage-gated potassium channel Kv10.1 has been 
studied intensely (Ouadid-Ahidouch et al. 2016; Pardo and 
Stuhmer 2014) in this context.
The idea of targeting Kv10.1 for therapy is not new. 
Channel blockers (e.g., Astemizole) and a specific block-
ing antibody decrease tumor cell proliferation in vitro and 
in vivo (de Guadalupe Chavez-Lopez et al. 2015; Downie 
et al. 2008; Garcia-Quiroz et al. 2014; Gomez-Varela et al. 
2007). However, for an effective tumor therapy it is not 
sufficient just to reduce the cancer cell proliferation. The 
cancer cells need to be eliminated to induce tumor regres-
sion. We designed a therapeutic fusion construct consisting 
of a Kv10.1-specific single-chain antibody and the apopto-
sis-inducing ligand TRAIL. TRAIL has been shown to be 
effective in eliminating cancer cells by inducing apoptosis 
and by fusing the ligand to a Kv10.1-specific antibody can 
overcome the limitations of the soluble TRAIL, like short 
half-life or less specificity (Hartung et al. 2011). In addi-
tion, resistance against TRAIL-induced apoptosis is a com-
mon phenomenon in cancer cells and is part of the immune 
escape strategy. The generation of a single-chain antibody 
TRAIL fusion offers several advantages. Compared to 
whole antibodies, single-chain antibodies are smaller and 
less immunogenic with a higher penetration rate, which is 
important for solid tumors (Yokota et al. 1992).
Roscovitine, etoposide, and doxorubicin are commonly 
used chemotherapeutic agents in cancer therapy (Baldwin 
and Osheroff 2005; Ortiz-Ferrón et al. 2008; Rivankar 
2014), but the development of resistance, especially in 
metastatic stages, remains a major obstacle of an effective 
tumor treatment (Wang et al. 2014).
We chose for our in vivo study the Kv10.1-positive 
metastatic cancer cell line MDA-MB435S, despite its dis-
puted origin (Lacroix 2009; Nerlich and Bachmeier 2013), 
because this model responds relatively well to anti-Kv10.1 
therapy and this was important for a proof-of-concept 
study. We used then low doses of a chemotherapeutic (dox-
orubicin) and increased the response to treatment using a 
scFv-TRAIL fusion.
To overcome the multidrug resistance in MDA-
MB435S, we used scFv62-TRAIL in combination with 
etoposide, roscovitine, and doxorubicin, and in all cases 
we observed an increase in apoptotic cells. A wide range 
Fig. 4  Influence of chemotherapeutic agents on expression of 
Kv10.1 and apoptotic receptors. MDA-MB435S cells were incu-
bated for 24 and 48 h with 20 μM roscovitine, 50 μM etoposide, or 
1.5 μM doxorubicin, and analyzed with quantitative real-time PCR 
for TRAIL-R1 (a), TRAIL-R2 (b), decoy receptors-R3 and -R4 at 
24 h treatment (c), and Kv10.1 expression (d) (two-way ANOVA, 
***p < 0.001; ****p < 0.0001)
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of chemotherapeutic drugs has been tested in combina-
tion with TRAIL (Gill et al. 2007; Ortiz-Ferrón et al. 2008; 
Shamimi-Noori et al. 2008; Singh et al. 2005; Wang et al. 
2010). The anthracycline antibiotic doxorubicin showed the 
highest apoptosis induction in the MDA-MB435S cells in 
combination with scFv62-TRAIL. TRAIL-mediated apop-
tosis is known to be increased in combination with doxo-
rubicin (Komdeur et al. 2004; Voelkel-Johnson et al. 2002; 
Wang et al. 2010), while resistance to both agents in isola-
tion is also reported (Xu et al. 2014; Zang et al. 2014).
To explore the mechanism underlying induction of apop-
tosis in combinational therapy, we blocked the TRAIL 
or the antibody part of our construct before treating the 
MDA-MB435S cells in the presence of doxorubicin; both 
approaches induced a decrease in apoptotic cells. Block 
of the TRAIL moiety was more efficient than block of the 
antibody, arguably because the construct can still act as sol-
uble TRAIL in the absence of membrane binding though 
Kv10.1.
The requirement of TRAIL activity was also shown 
by siRNA-mediated downregulation of the TRAIL death 
receptors. We observed no change in the apoptosis induc-
tion, when only one receptor is downregulated, and only 
the inhibition of the expression of both receptors blocked 
the apoptosis induction. Therefore, our scFv62-TRAIL 
antibody can induce, in combination with chemotherapy, 
apoptosis via both death receptors in MDA-MB435S cells.
The MDA-MB435S cells are not sensitive to our 
scFv62-TRAIL construct or soluble TRAIL alone. There 
are several cellular changes that can lead to TRAIL resist-
ance. One highly discussed factor is the expression level 
and composition of proapoptotic and decoy receptors (Ric-
cioni et al. 2005; Sanlioglu et al. 2005). TRAIL-R1 and 
TRAIL-R2 are expressed in MDA-MB435S cells. Both 
death receptors are upregulated in the MDA-MB435S cells 
after sensitizing with doxorubicin and etoposide (Fig. 4), 
suggesting involvement of death receptor expression levels 
in TRAIL resistance of this cell line. The decoy receptors 
do not seem to contribute to TRAIL resistance in MDA-
MB435S cells since TRAIL-R3 is weakly expressed and 
TRAIL-R4 is undetectable. Other studies found no cor-
relation between decoy receptor expression and resistance 
to TRAIL in various cancer cell types (Mahalingam et al. 
2009).
Upregulation of death receptors can be an explanation 
for the increase in apoptotic induction upon pre-treatment 
with chemotherapeutics (Fig. 4), because the TRAIL recep-
tors would be more abundant in the cells before TRAIL 
treatment. Upregulation of TRAIL receptors R1 and R2 
upon activation of p53 and/or NF-κB as a result of subtoxic 
doses of doxorubicin, etoposide, and other chemotherapeu-
tic drugs are well documented (Gibson et al. 2000; Kang 
et al. 2005; Lee et al. 2002). Whether or not this is actually 
the mechanism responsible for the upregulation observed 
here has not been studied. Decoy receptors TRAIL-R3 and 
-R4 can also be upregulated by p53 (Meng et al. 2000), but 
the levels detected in our cell lines are only marginal even 
after chemotherapeutic drug treatment, and therefore it is 
unlikely that they play a role in inducing resistance.
The increase in Kv10.1 levels observed with etoposide 
alone could be due to arrest in G2 phase of the cell cycle, 
which is the moment when expression of Kv10.1 peaks in 
other cell types (Urrego et al. 2016).
scFv62-TRAIL in combination with doxorubicin also 
showed efficacy in vivo. We used a relative low amount of 
0.9 mg/kg doxorubicin and 0.15 mg/kg scFv62-TRAIL per 
mouse in comparison with other studies (Vitovski et al. 2012; 
Wang et al. 2010), but the effect was still clearly observable. 
We noticed no evidence of increased aggressiveness of the 
tumors in the treated animals (von Karstedt et al. 2015). 
Nevertheless, experiments in mice with an intact immune 
systems would be required to progress along this line.
Fig. 5  Pre-treatment increases apoptosis induction. a MDA-MB435S 
cells were treated with different concentrations of doxorubicin in 
combination with scFv62-TRAIL (0.1 μg/ml) for 18 h or pre-treated 
with doxorubicin for 24 h and then with scFv62-TRAIL (0.1 μg/ml) 
for 18 h. Afterwards, cells were analyzed with Annexin V staining 
and flow cytometry. b MDA-MB435S cells were treated with doxo-
rubicin for 24 h and afterwards with scFv62-TRAIL for different time 
spans in presence (red columns) or absence of doxorubicin (white col-
umns). After 18 h, apoptosis induction was measured using Annexin 
V staining and flow cytometry (two-way ANOVA, **p < 0.01; 
***p < 0.001; ****p < 0.0001)
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As a general conclusion, we provide here the in vivo 
proof of concept of the use of scFv62-TRAIL to overcome 
resistance to doxorubicin in Kv10.1-positive tumors.
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